Monitoring for metabolic side effects among outpatients with dementia receiving antipsychotics.

Mittal D, Li C, Viverito K, Williams JS, Landes RD, Thapa PB, Owen R. Monitoring for metabolic side effects among outpatients with dementia receiving antipsychotics. Psychiatric services (Washington, D.C.). 2014 Sep 1; 65(9):1147-53.

Related HSR&D Project(s)

• SHP 08-146 – Management of Metabolic Side Effects of Antipsychotics in Six VISNs

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

OBJECTIVE: This study examined monitoring for metabolic side effects among older outpatients with dementia starting a new antipsychotic. METHODS: In a retrospective cohort analysis of U.S. Department of Veterans Affairs data, monitoring, as recommended by the American Diabetes Association and the American Psychiatric Association, was examined between October 1, 2005, and September 30, 2011. The sample included outpatients aged = 60 years with dementia but without a psychotic disorder (N = 3,903) and outpatients with a psychotic disorder but without dementia (N = 5,779) who were prescribed a new antipsychotic. Because dementia patients differed from psychosis patients in all observed patient characteristics, especially age, metabolic monitoring of dementia patients was compared with a propensity score-matched sample of outpatients with psychosis (1,576 matched pairs). RESULTS: At baseline (±30 days from the index prescription), 68% of the matched dementia patients were weighed, compared with 63.7% of the matched psychosis patients (odds ratio [OR] = 1.28, 95% confidence interval [CI] = 1.03-1.48). Monitoring for glucose or glycosylated hemoglobin (HBA1c) and low-density lipoprotein (LDL) was not significantly different between the groups: glucose or HBA1c, 41% versus 44%; LDL, 24% versus 27%. At three months (±30 days), metabolic monitoring for all three parameters was significantly lower for the dementia group: weight, OR = .86, CI = .75-.99; glucose or HBA1c, OR = .83, CI = .71-.97; and LDL, OR = .69, CI = .57-.85. CONCLUSIONS: Monitoring rates for metabolic side effects were low for both dementia and psychosis groups, with lower rates for dementia patients at follow-up compared with matched psychosis patients. Quality improvement efforts are needed to improve monitoring, especially for patients with dementia.